Cybin (NEO: CYBN) CEO Doug Drysdale was featured on a recent episode of TraderTV Live. Broadcast live from the DTTW trading floor, TraderTV Live is the first and only professional trading show on YouTube Live. During the show, Drysdale discussed Cybin’s work on psychedelic medical research, including the company’s current phase 2 study. He also provided an overview of Cybin’s strategic plan moving forward in the development process. In addition, Drysdale talked about the company recent listing move to the NEO exchange and plans for an uplisting to a U.S. exchange in the future. “We recently closed our series B go public round for $45 million Canadian,” said Drysdale during the interview. “This is the largest round in psychedelics in Canada in history. And very fortunate that the book was filled about 95% by U.S. biotech funds, so very flattering and strong validation of the science and of the mission. We’re developing psychedelic therapeutic products for mental illness, and our lead clinical program is for major depressive disorder. We’re looking to kick off a clinical study at the beginning of 2021.”
To view the full interview, visit https://ibn.fm/ONU6i
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.